Gellan gum spongy-like hydrogel-based dual antibiotic therapy for infected diabetic wounds

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorMENDES, Ana Isabel
dc.contributor.authorFRAGA, Alexandra Gabriel
dc.contributor.authorPEIXOTO, Maria Joao
dc.contributor.authorAROSO, Ivo
dc.contributor.authorLONGATTO-FILHO, Adhemar
dc.contributor.authorMARQUES, Alexandra Pinto
dc.contributor.authorPEDROSA, Jorge
dc.date.accessioned2023-12-15T18:58:54Z
dc.date.available2023-12-15T18:58:54Z
dc.date.issued2023
dc.description.abstractDiabetic foot infection (DFI) is an important cause of morbidity and mortality. Antibiotics are fundamental for treating DFI, although bacterial biofilm formation and associated pathophysiology can reduce their effectiveness. Additionally, antibiotics are often associated with adverse reactions. Hence, improved antibiotic therapies are required for safer and effective DFI management. On this regard, drug delivery systems (DDSs) constitute a promising strategy. We propose a gellan gum (GG)-based spongy-like hydrogel as a topical and controlled DDS of vancomycin and clindamycin, for an improved dual antibiotic therapy against methicillin-resistant Staphylococcus aureus (MRSA) in DFI. The developed DDS presents suitable features for topical application, while promoting the controlled release of both antibiotics, resulting in a significant reduction of in vitro antibiotic-associated cytotoxicity without compromising antibacterial activity. The therapeutic potential of this DDS was further corroborated in vivo, in a diabetic mouse model of MRSA-infected wounds. A single DDS administration allowed a significant bacterial burden reduction in a short period of time, without exacerbating host inflammatory response. Taken together, these results suggest that the proposed DDS represents a promising strategy for the topical treatment of DFI, potentially overcoming limitations associated with systemic antibiotic administration and minimizing the frequency of administration.eng
dc.description.indexPubMed
dc.description.indexWoS
dc.description.indexScopus
dc.description.sponsorshipEuropean Social Fund [UMINHO/BD/53/2017]
dc.description.sponsorshipFundacao para a Ciencia e a Tecnologia [UIDB/50026/2020, UIDP/50026/2020]
dc.identifier.citationBIOENGINEERING & TRANSLATIONAL MEDICINE, v.8, n.3, 2023
dc.identifier.doi10.1002/btm2.10504
dc.identifier.eissn2380-6761
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/57585
dc.language.isoeng
dc.publisherWILEYeng
dc.relation.ispartofBioengineering & Translational Medicine
dc.rightsopenAccesseng
dc.rights.holderCopyright WILEYeng
dc.subjectantibioticseng
dc.subjectdiabetic ulcerseng
dc.subjecthydrogeleng
dc.subjectMRSA infectioneng
dc.subjecttopical deliveryeng
dc.subject.otherin-vitro activityeng
dc.subject.otherfoot infectionseng
dc.subject.otherdeliveryeng
dc.subject.otherchloramphenicoleng
dc.subject.othermicroparticleseng
dc.subject.othernanoparticleseng
dc.subject.otherclindamycineng
dc.subject.othermanagementeng
dc.subject.otherbiofilmseng
dc.subject.othersulfateeng
dc.subject.wosBiotechnology & Applied Microbiologyeng
dc.subject.wosEngineering, Biomedicaleng
dc.subject.wosPharmacology & Pharmacyeng
dc.titleGellan gum spongy-like hydrogel-based dual antibiotic therapy for infected diabetic woundseng
dc.typearticleeng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng
dspace.entity.typePublication
hcfmusp.affiliation.countryPortugal
hcfmusp.affiliation.countryisopt
hcfmusp.author.externalMENDES, Ana Isabel:Univ Minho, Life & Hlth Sci Res Inst ICVS, Sch Med, Braga, Portugal; ICVS, PT Govt Associate Lab 3Bs, Braga Guimaraes, Portugal
hcfmusp.author.externalFRAGA, Alexandra Gabriel:Univ Minho, Life & Hlth Sci Res Inst ICVS, Sch Med, Braga, Portugal; ICVS, PT Govt Associate Lab 3Bs, Braga Guimaraes, Portugal
hcfmusp.author.externalPEIXOTO, Maria Joao:Univ Minho, Life & Hlth Sci Res Inst ICVS, Sch Med, Braga, Portugal; ICVS, PT Govt Associate Lab 3Bs, Braga Guimaraes, Portugal
hcfmusp.author.externalAROSO, Ivo:ICVS, PT Govt Associate Lab 3Bs, Braga Guimaraes, Portugal; Univ Minho, Res Inst Biomat Biodegradables & Biomimet I3Bs, Headquarters European Inst Excellence Tissue Engn, Res Grp 3Bs, Guimaraes, Portugal
hcfmusp.author.externalMARQUES, Alexandra Pinto:ICVS, PT Govt Associate Lab 3Bs, Braga Guimaraes, Portugal; Univ Minho, Res Inst Biomat Biodegradables & Biomimet I3Bs, Headquarters European Inst Excellence Tissue Engn, Res Grp 3Bs, Guimaraes, Portugal
hcfmusp.author.externalPEDROSA, Jorge:Univ Minho, Life & Hlth Sci Res Inst ICVS, Sch Med, Braga, Portugal; ICVS, PT Govt Associate Lab 3Bs, Braga Guimaraes, Portugal; Univ Minho, Life & Hlth Sci Res Inst ICVS, Sch Med, Campus Gualtar, P-4710057 Braga, Portugal
hcfmusp.citation.scopus3
hcfmusp.contributor.author-fmusphcADHEMAR LONGATTO FILHO
hcfmusp.description.issue3
hcfmusp.description.volume8
hcfmusp.origemWOS
hcfmusp.origem.pubmed37206216
hcfmusp.origem.scopus2-s2.0-85150901213
hcfmusp.origem.wosWOS:000956374100001
hcfmusp.publisher.cityHOBOKENeng
hcfmusp.publisher.countryUSAeng
hcfmusp.relation.referenceAhmad S, 2019, INT J BIOL MACROMOL, V136, P870, DOI 10.1016/j.ijbiomac.2019.06.113eng
hcfmusp.relation.referenceAnjum A, 2018, AAPS PHARMSCITECH, V19, P1219, DOI 10.1208/s12249-017-0937-4eng
hcfmusp.relation.reference[Anonymous], 1985, WHO TECH REP SER, P1eng
hcfmusp.relation.reference[Anonymous], 2008, SMALL ANIMAL CLIN PHeng
hcfmusp.relation.referenceArmstrong DG, 2017, NEW ENGL J MED, V376, P2367, DOI 10.1056/NEJMra1615439eng
hcfmusp.relation.referenceAtkin L, 2019, J WOUND CARE, V28, pS5, DOI 10.12968/jowc.2019.28.Sup3a.S1eng
hcfmusp.relation.referenceAttinger C, 2012, ADV WOUND CARE, V1, P127, DOI 10.1089/wound.2011.0333eng
hcfmusp.relation.referenceBarwell ND, 2017, INT J CLIN PRACT, V71, DOI 10.1111/ijcp.13006eng
hcfmusp.relation.referenceBera H, 2018, INT J BIOL MACROMOL, V107, P604, DOI 10.1016/j.ijbiomac.2017.09.027eng
hcfmusp.relation.referenceBerti FV, 2017, TISSUE ENG PT A, V23, P968, DOI [10.1089/ten.tea.2016.0430, 10.1089/ten.TEA.2016.0430]eng
hcfmusp.relation.referenceCarmona-Moran CA, 2016, INT J PHARMACEUT, V509, P465, DOI 10.1016/j.ijpharm.2016.05.062eng
hcfmusp.relation.referenceCavanagh PR, 2005, LANCET, V366, P1725, DOI 10.1016/S0140-6736(05)67699-4eng
hcfmusp.relation.referenceCerqueira MT, 2014, ACS APPL MATER INTER, V6, P19668, DOI 10.1021/am504520jeng
hcfmusp.relation.referenceCitron DM, 2007, J CLIN MICROBIOL, V45, P2819, DOI 10.1128/JCM.00551-07eng
hcfmusp.relation.referenceCLSI (Clinical and Laboratory Standards Institute), 2021, CLSI supplement M100, V31st, P352eng
hcfmusp.relation.referenceCong YG, 2020, J ADV RES, V21, P169, DOI 10.1016/j.jare.2019.10.005eng
hcfmusp.relation.referenceCrouzet J, 2011, INT J INFECT DIS, V15, pE601, DOI 10.1016/j.ijid.2011.05.003eng
hcfmusp.relation.referenceda Silva LP, 2016, ACS APPL MATER INTER, V8, P33464, DOI 10.1021/acsami.6b11684eng
hcfmusp.relation.referenceda Silva LP, 2014, ACTA BIOMATER, V10, P4787, DOI 10.1016/j.actbio.2014.07.009eng
hcfmusp.relation.referenceda Silva LP, 2017, J INVEST DERMATOL, V137, P1541, DOI 10.1016/j.jid.2017.02.976eng
hcfmusp.relation.referenceDhanka M, 2018, INT J BIOL MACROMOL, V110, P346, DOI 10.1016/j.ijbiomac.2017.12.026eng
hcfmusp.relation.referenceDimitrovska I, 2020, CELLULOSE, V27, P7109, DOI 10.1007/s10570-020-03283-7eng
hcfmusp.relation.referenceDorati R, 2016, MAT SCI ENG C-MATER, V58, P909, DOI 10.1016/j.msec.2015.09.053eng
hcfmusp.relation.referenceDutescu IA, 2021, INFECT DRUG RESIST, V14, P415, DOI 10.2147/IDR.S287792eng
hcfmusp.relation.referenceDzikowski M, 2017, INT J PHARMACEUT, V532, P802, DOI 10.1016/j.ijpharm.2017.08.117eng
hcfmusp.relation.referenceEleftheriadou L, 2010, DRUGS, V70, P1785, DOI 10.2165/11538070-000000000-00000eng
hcfmusp.relation.referenceFalcone M, 2021, J GLOB ANTIMICROB RE, V26, P140, DOI 10.1016/j.jgar.2021.05.010eng
hcfmusp.relation.referenceFerris CJ, 2013, SOFT MATTER, V9, P3705, DOI 10.1039/c3sm27389jeng
hcfmusp.relation.referenceFriedman ND, 2016, CLIN MICROBIOL INFEC, V22, P416, DOI 10.1016/j.cmi.2015.12.002eng
hcfmusp.relation.referenceFurman Brian L, 2021, Curr Protoc, V1, pe78, DOI 10.1002/cpz1.78eng
hcfmusp.relation.referenceGustafson CT, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146401eng
hcfmusp.relation.referenceHasan N, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11050236eng
hcfmusp.relation.referenceHu SX, 2019, INT J BIOL MACROMOL, V123, P1320, DOI 10.1016/j.ijbiomac.2018.09.122eng
hcfmusp.relation.referenceISO, 2009, ISO 10993-5: 2009eng
hcfmusp.relation.referenceKalita H, 2017, RSC ADV, V7, P32637, DOI 10.1039/c7ra04888beng
hcfmusp.relation.referenceKalita S, 2015, INT J NANOMED, V10, P2971, DOI 10.2147/IJN.S75023eng
hcfmusp.relation.referenceKaur P, 2019, INT J PHARMACEUT, V572, DOI 10.1016/j.ijpharm.2019.118779eng
hcfmusp.relation.referenceKim MH, 2016, IEEE T NANOBIOSCI, V15, P294, DOI 10.1109/TNB.2016.2527600eng
hcfmusp.relation.referenceKumar S, 2021, ACS APPL MATER INTER, V13, P44041, DOI 10.1021/acsami.1c12265eng
hcfmusp.relation.referenceLeaper D, 2015, BRIT J DERMATOL, V173, P351, DOI 10.1111/bjd.13677eng
hcfmusp.relation.referenceLi AQ, 2021, DRUG DES DEV THER, V15, P3937, DOI 10.2147/DDDT.S328722eng
hcfmusp.relation.referenceLiang YP, 2022, ACS NANO, V16, P3194, DOI 10.1021/acsnano.1c11040eng
hcfmusp.relation.referenceLipsky BA, 2016, DIABETES-METAB RES, V32, P45, DOI 10.1002/dmrr.2699eng
hcfmusp.relation.referenceLipsky BA, 2012, CLIN INFECT DIS, V54, P1679, DOI [10.1093/cid/cis460, 10.1093/cid/cis346]eng
hcfmusp.relation.referenceMahdi MH, 2016, INT J PHARMACEUT, V515, P535, DOI 10.1016/j.ijpharm.2016.10.048eng
hcfmusp.relation.referenceMalone M., 2017, DIABETES-METAB RES, V33, P7eng
hcfmusp.relation.referenceMaver T, 2021, MATERIALS, V14, DOI 10.3390/ma14061464eng
hcfmusp.relation.referenceMendes AI, 2022, BMC RES NOTES, V15, DOI 10.1186/s13104-022-06170-5eng
hcfmusp.relation.referenceMohamed AI, 2017, PHARMACEUTICS, V9, DOI 10.3390/pharmaceutics9010007eng
hcfmusp.relation.referenceMorley R, 2022, J FOOT ANKLE SURG, V61, P239, DOI 10.1053/j.jfas.2021.07.014eng
hcfmusp.relation.referenceMottola C, 2016, BMC MICROBIOL, V16, DOI 10.1186/s12866-016-0737-0eng
hcfmusp.relation.referenceMurphy PB., 2022, CLINDAMYCINeng
hcfmusp.relation.referenceMuthukumar T, 2019, MOLECULES, V24, DOI 10.3390/molecules24244514eng
hcfmusp.relation.referenceNair AB, 2019, POLYMERS-BASEL, V11, DOI 10.3390/polym11101699eng
hcfmusp.relation.referenceOlid AS., 2015, COCHRANE DB SYST REV, V9, P113eng
hcfmusp.relation.referenceOliveira JT, 2010, J BIOMED MATER RES A, V93A, P852, DOI 10.1002/jbm.a.32574eng
hcfmusp.relation.referencePatel S., 2022, VANCOMYCINeng
hcfmusp.relation.referencePatel S, 2019, BIOMED PHARMACOTHER, V112, DOI 10.1016/j.biopha.2019.108615eng
hcfmusp.relation.referencePletz MW, 2017, LANCET INFECT DIS, V17, P677, DOI 10.1016/S1473-3099(17)30233-5eng
hcfmusp.relation.referencePosadowska U, 2016, J MATER SCI-MATER M, V27, DOI 10.1007/s10856-015-5604-2eng
hcfmusp.relation.referencePrezotti FG, 2014, CARBOHYD POLYM, V113, P286, DOI 10.1016/j.carbpol.2014.07.021eng
hcfmusp.relation.referenceRoy DC, 2015, ADV WOUND CARE, V4, P457, DOI 10.1089/wound.2014.0576eng
hcfmusp.relation.referenceRufato KB, 2021, INT J BIOL MACROMOL, V183, P727, DOI 10.1016/j.ijbiomac.2021.04.138eng
hcfmusp.relation.referenceSalunke SR, 2016, INT J BIOL MACROMOL, V87, P41, DOI 10.1016/j.ijbiomac.2016.02.044eng
hcfmusp.relation.referenceSchultz G, 2017, WOUND REPAIR REGEN, V25, P744, DOI 10.1111/wrr.12590eng
hcfmusp.relation.referenceSilva V, 2020, EUR J CLIN MICROBIOL, V39, P179, DOI 10.1007/s10096-019-03709-6eng
hcfmusp.relation.referenceSMILACK JD, 1991, MAYO CLIN PROC, V66, P1270, DOI 10.1016/S0025-6196(12)62479-3eng
hcfmusp.relation.referenceSrisuk P, 2018, ACS BIOMATER SCI ENG, V4, P1779, DOI 10.1021/acsbiomaterials.7b00917eng
hcfmusp.relation.referenceSun H, 2022, DIABETES RES CLIN PR, V183, DOI 10.1016/j.diabres.2021.109119eng
hcfmusp.relation.referenceVersey Z, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.648554eng
hcfmusp.relation.referenceWang B, 2019, POWDER TECHNOL, V358, P79, DOI 10.1016/j.powtec.2018.07.084eng
hcfmusp.relation.referenceWATANAKUNAKORN C, 1984, J ANTIMICROB CHEMOTH, V14, P7, DOI 10.1093/jac/14.suppl_D.7eng
hcfmusp.relation.referenceXiong MH, 2014, ADV DRUG DELIVER REV, V78, P63, DOI 10.1016/j.addr.2014.02.002eng
hcfmusp.relation.referenceZakeri-Milani P, 2013, COLLOID SURFACE B, V103, P174, DOI 10.1016/j.colsurfb.2012.10.021eng
hcfmusp.scopus.lastupdate2024-04-12
relation.isAuthorOfPublication4401f59e-efe8-4a24-9f39-0b6bde3c72b7
relation.isAuthorOfPublication.latestForDiscovery4401f59e-efe8-4a24-9f39-0b6bde3c72b7
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
art_MENDES_Gellan_gum_spongylike_hydrogelbased_dual_antibiotic_therapy_for_2023.PDF
Tamanho:
4.39 MB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/Outros
Artigos e Materiais de Revistas Científicas - LIM/14
Artigos e Materiais de Revistas Científicas - ODS/03